Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for Ureaplasma Spp. and Mycoplasma hominis

Lefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 Ureaplasma parvum,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Oliver Spiller-Boulter, Susanne Paukner, Ian Boostrom, Kirsty Sands, Edward A. R. Portal, Owen B. Spiller
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	lefamulin <i>Mycoplasma hominis</i> <i>Ureaplasma</i> spp. pleuromutilin susceptibility testing Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/bc719c3f63ca4dcc8b8fbc8c3bbac62d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bc719c3f63ca4dcc8b8fbc8c3bbac62d
record_format	dspace
spelling	oai:doaj.org-article:bc719c3f63ca4dcc8b8fbc8c3bbac62d2021-11-25T16:24:00ZDetermination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>10.3390/antibiotics101113702079-6382https://doaj.org/article/bc719c3f63ca4dcc8b8fbc8c3bbac62d2021-11-01T00:00:00Zhttps://www.mdpi.com/2079-6382/10/11/1370https://doaj.org/toc/2079-6382Lefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 <i>Ureaplasma</i> <i>parvum</i>, 25 <i>Ureaplasma urealyticum,</i> and 40 <i>Mycoplasma hominis</i>). All <i>Mycoplasma hominis</i> isolates possessed lefamulin MICs of ≤0.25 mg/L after 48 h (MIC<sub>50/90</sub> of 0.06/0.12 mg/L), despite an inherent resistance to macrolides; while <i>Ureaplasma</i> isolates had MICs of ≤2 mg/L after 24 h (MIC<sub>50/90</sub> of 0.25/1 mg/L), despite inherent resistance to clindamycin. Two <i>U. urealyticum</i> isolates with additional A2058G mutations of 23S rRNA, and one <i>U. parvum</i> isolate with a R66Q67 deletion (all of which had a combined resistance to macrolides and clindamycin) only showed a 2-fold increase in lefamulin MIC (1–2 mg/L) relative to macrolide-susceptible strains. Lefamulin could be an effective alternative antimicrobial for treating <i>Ureaplasma</i> spp. and <i>Mycoplasma hominis</i> infections irrespective of intrinsic or acquired resistance to macrolides, lincosamides, and ketolides. Based on this potent in vitro activity and the known good, rapid, and homogenous tissue penetration of female and male urogenital tissues and glands, further exploration of clinical efficacy of lefamulin for the treatment of <i>Mycoplasma</i> and <i>Ureaplasma</i> urogenital infections is warranted.Oliver Spiller-BoulterSusanne PauknerIan BoostromKirsty SandsEdward A. R. PortalOwen B. SpillerMDPI AGarticlelefamulin<i>Mycoplasma hominis</i><i>Ureaplasma</i> spp.pleuromutilinsusceptibility testingTherapeutics. PharmacologyRM1-950ENAntibiotics, Vol 10, Iss 1370, p 1370 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lefamulin <i>Mycoplasma hominis</i> <i>Ureaplasma</i> spp. pleuromutilin susceptibility testing Therapeutics. Pharmacology RM1-950
spellingShingle	lefamulin <i>Mycoplasma hominis</i> <i>Ureaplasma</i> spp. pleuromutilin susceptibility testing Therapeutics. Pharmacology RM1-950 Oliver Spiller-Boulter Susanne Paukner Ian Boostrom Kirsty Sands Edward A. R. Portal Owen B. Spiller Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>
description	Lefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 <i>Ureaplasma</i> <i>parvum</i>, 25 <i>Ureaplasma urealyticum,</i> and 40 <i>Mycoplasma hominis</i>). All <i>Mycoplasma hominis</i> isolates possessed lefamulin MICs of ≤0.25 mg/L after 48 h (MIC<sub>50/90</sub> of 0.06/0.12 mg/L), despite an inherent resistance to macrolides; while <i>Ureaplasma</i> isolates had MICs of ≤2 mg/L after 24 h (MIC<sub>50/90</sub> of 0.25/1 mg/L), despite inherent resistance to clindamycin. Two <i>U. urealyticum</i> isolates with additional A2058G mutations of 23S rRNA, and one <i>U. parvum</i> isolate with a R66Q67 deletion (all of which had a combined resistance to macrolides and clindamycin) only showed a 2-fold increase in lefamulin MIC (1–2 mg/L) relative to macrolide-susceptible strains. Lefamulin could be an effective alternative antimicrobial for treating <i>Ureaplasma</i> spp. and <i>Mycoplasma hominis</i> infections irrespective of intrinsic or acquired resistance to macrolides, lincosamides, and ketolides. Based on this potent in vitro activity and the known good, rapid, and homogenous tissue penetration of female and male urogenital tissues and glands, further exploration of clinical efficacy of lefamulin for the treatment of <i>Mycoplasma</i> and <i>Ureaplasma</i> urogenital infections is warranted.
format	article
author	Oliver Spiller-Boulter Susanne Paukner Ian Boostrom Kirsty Sands Edward A. R. Portal Owen B. Spiller
author_facet	Oliver Spiller-Boulter Susanne Paukner Ian Boostrom Kirsty Sands Edward A. R. Portal Owen B. Spiller
author_sort	Oliver Spiller-Boulter
title	Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>
title_short	Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>
title_full	Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>
title_fullStr	Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>
title_full_unstemmed	Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>
title_sort	determination of in vitro antimicrobial susceptibility for lefamulin (pleuromutilin) for <i>ureaplasma</i> spp. and <i>mycoplasma hominis</i>
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/bc719c3f63ca4dcc8b8fbc8c3bbac62d
work_keys_str_mv	AT oliverspillerboulter determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi AT susannepaukner determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi AT ianboostrom determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi AT kirstysands determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi AT edwardarportal determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi AT owenbspiller determinationofinvitroantimicrobialsusceptibilityforlefamulinpleuromutilinforiureaplasmaisppandimycoplasmahominisi
_version_	1718413223322976256

Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for <i>Ureaplasma</i> Spp. and <i>Mycoplasma hominis</i>

Ejemplares similares